-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND__0399_01-07-2011.pdf
January 01, 2011 - brachytherapy, RE; D) liver-directed chemotherapy, including hepatic artery infusion
(HAI) chemotherapy, TACE, drug-eluting … brachytherapy, RE; D) liver-directed chemotherapy, including hepatic artery infusion
(HAI) chemotherapy, TACE, drug-eluting
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/antidepressants-update_executive.pdf
December 01, 2011 - (i.e.,
continuation phase) or recurrence (i.e., maintenance
phase) when a patient:
• continues the drug … indications (major
depressive disorder, dysthymia, minor depression,
subsyndromal depressive disorder), drug … We assessed statistically each of the 78 possible drug
comparisons of second-generation antidepressants … full-text articles excluded:
7 Foreign languages
10 Too short of duration
84 Wrong population
142 Wrong drug … meta-analyses on the response to
treatment (at least 50 percent improvement from
baseline) for six drug–drug
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/diabetes-update-2015_research-protocol.pdf
January 01, 2015 - Food and Drug
Administration (FDA) for treatment of type 2 diabetes. … benefit
and risk attributable to these drugs or may alter the strength of evidence on some of the drug … Center for Drug Evaluation and Research. Guidance for Industry. … Food and Drug Administration. … FDA Drug Safety Communication: FDA requires
removal of some prescribing and dispensing restrictions
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/allergy-seasonal_research-protocol.pdf
March 08, 2012 - Food and Drug
Administration (FDA) for the treatment of SAR. … Drug class review: nasal corticosteroids: final report
update 1. … Drug class review: newer antihistamines: final report update 2. … Food and Drug AdministrationCenter for Drug Evaluation and Research. … Food and Drug Administration; April 2000.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/prostatic-hyperplasia-medications_research-protocol.pdf
April 21, 2015 - In the early 1990s, the Federal Drug Administration (FDA) approval of medications for
BPH shifted LUTS … prostates with
either agent are supported by systematic reviews.10, 13
Recently, newer drugs and other drug … Common medications used to treat LUTS associated with BPH
Drug class -
Mechanism of action Medication … , drug manufacturer, device
trade name, keyword]
109. exp Product Surveillance, Postmarketing/
110 … . exp "Drug-Related Side Effects and Adverse Reactions"/
111. exp Adverse Drug Reaction Reporting Systems
-
effectivehealthcare.ahrq.gov/products/mental-illness-employment/abstract
December 20, 2011 - and somatic chronic care; and (3) patient-reported outcomes, including functional status, alcohol and drug
-
effectivehealthcare.ahrq.gov/get-involved/nominated-topics/comparative-effectiveness-for-the-treatment-of-major-depressive-disorder-mdd-key-questions-1-for-the-treatment-of-mdd-what-is-the-comparative-effectiveness-of-ssris-placebo-psychotherapy-exercise-and-alternative-therapies-2-f
March 11, 2013 - Appropriateness for EHC Program
Does your question include a health care drug, intervention, device
-
effectivehealthcare.ahrq.gov/get-involved/nominated-topics/please-help-find-something-to-ease-my-mothers-pain-with-restless-leg-syndrome-it-has-bothered-her-for-over-30-years-and-now-is-almost-unbearable-at-78-years-old-it-has-really-diminished-her-joy-in-life
January 06, 2010 - Appropriateness for EHC Program
Does your question include a health care drug, intervention, device
-
effectivehealthcare.ahrq.gov/get-involved/nominated-topics/what-are-the-best-options-for-fertility-treatment-in-terms-of-safety-and-effectiveness
January 31, 2013 - None
Appropriateness for EHC Program
Does your question include a health care drug, intervention
-
effectivehealthcare.ahrq.gov/get-involved/nominated-topics/is-there-an-easier-way-to-test-for-celiac-disease
March 11, 2012 - Appropriateness for EHC Program
Does your question include a health care drug, intervention, device
-
effectivehealthcare.ahrq.gov/sites/default/files/06_devdelays_autism_potential_high_impact_june_2012.pdf
January 01, 2012 - similar drugs in the same class are read separately), and then topics in the same class of a
device, drug
-
effectivehealthcare.ahrq.gov/products/tinnitus/research
August 23, 2013 - Current Page Topic Timeline Feb. 17, 2012 Topic Suggestion Feb. 22, 2012 Research Protocol Aug. 23, 2013 Systematic Review Nov. 27, 2013 Disposition of Comments Report Evaluation and Treatment of Tinnitus: Comparative Effectiveness
Systematic Review Archived August 23, 2013 Web Version [NLM Site] Download Main Doc…
-
effectivehealthcare.ahrq.gov/products/dementia-databases-methods/research
May 22, 2008 - Preventive Medicine, University of Maryland School of Medicine, Baltimore, MD. 2 Peter Lamy Center on Drug … settings was also found despite the different method of measuring medication use, with institutional drug … This relationship also held in the community, albeit overall rates of drug use were lower (15.5% versus … particularly important to replicate this work given that new drugs (specifically memantine) and other drug … The quality of antipsychotic drug prescribing in nursing homes.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/psoriasis-chronic_executive.pdf
November 01, 2012 - etanercept, and adalimumab), and
one anti-IL 12/23 agent (ustekinumab) have approval
from the Food and Drug … agents concluded a difference in efficacy, suggesting
heterogeneity within the class and indicating drug … and therefore do not make between-class
comparisons, rather limit comparisons with the individual
drug … systemic biologic
agents and systemic nonbiologic agents (between-class
comparisons on an individual drug … systemic biologic
agents and systemic nonbiologic agents (between-class
comparisons on an individual drug
-
effectivehealthcare.ahrq.gov/products/antidepressants-update/research-protocol
July 13, 2011 - relapse (i.e., continuation phase) or recurrence (i.e., maintenance phase) when a patient continues the drug … medications with new formulations (such as an extended release formulation) are approved by the Food and Drug … Administration (FDA) through an application called a supplemental new drug application (sNDA). … of interest is whether response or remission can be maintained if patients who have responded to one drug … If fewer than three head-to-head trials are available for any drug comparison, we will compute indirect
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/antidepressants-update_research-protocol.pdf
July 13, 2011 - , continuation phase) or recurrence (i.e.,
maintenance phase) when a patient
1) continues the drug … medications
with new formulations (such as an extended release formulation) are approved by the
Food and Drug … Administration (FDA) through an application called a supplemental new
drug application (sNDA). … interest is whether response or
remission can be maintained if patients who have responded to one drug … If fewer than three
head-to-head trials are available for any drug comparison, we will compute indirect
-
effectivehealthcare.ahrq.gov/sites/default/files/developmental-delays-horizon-scan-high-impact-1506.pdf
December 01, 2015 - similar drugs in the same class are read separately), and then topics in the same class of a
device, drug … study examining metadoxine for treating adult ADHD; a similar
trial is also planned to study this drug
-
effectivehealthcare.ahrq.gov/sites/default/files/pregnancy-horizon-scan-high-impact-1412.pdf
December 01, 2014 - similar drugs in the same class are read separately), and then topics in the same class of a
device, drug … spontaneous preterm birth; interventions intended to target both
the pregnant woman and fetus (a drug
-
effectivehealthcare.ahrq.gov/products/cognitive-decline/research-2017
March 24, 2017 - Many interventions (e.g., nutraceuticals; one multimodal intervention using lifestyle advice and drug
-
effectivehealthcare.ahrq.gov/sites/default/files/substance-abuse-horizon-scan-high-impact-1512.pdf
December 01, 2015 - Recent marketing data collected by the FDA’s
Center for Drug Evaluation and Research indicates that … The drug potentially holds additional promise as an AUD therapy because its safety
profile is better … Hazardous
drinkers and drug users in HMO primary care:
prevalence, medical conditions, and costs. … Mobile medical applications: guidance for industry
and Food and Drug Administration staff. … Food and Drug Administration
(FDA); 2015 Feb 9. 44 p.